TTY Biopharm specializes in the research and development of drugs for cancer, anti-infection, cardiovascular, and central nerves diseases. With strict assessment procedures for new products and patent analysis, outstanding development capability of our formulation R&D center, and the long-term established scientific data on clinical trials, we develop ourselves to be the leading drug development company in Taiwan and enter the global market with high-barrier to competition and effective drugs of innovative formulations to become the best partner of the companies that are competitive in drug promotion in the target market.

TTY Biopharm will invest expertise in core technologies, focus on marketing core products and core markets to develop a superior pharmaceutical R&D value chain, and establish strategic alliances with international biopharmaceutical companies as well as construct an enterprise that possesses competitive advantages in the new century.

Short-term: Apply current core technologies, such as sustained-release and liposome technologies, to develop new drug delivery systems and target-aiming remedies.

Mid-term: Build upon current technology and knowledge platforms to research and develop medications for prevalent Chinese diseases and be engaged in research on utilizing existing compositions to develop new indications to obtain patented new drugs.